Biomarkers identified for prostate cancer patients through genome-scale screening
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1437 views | HTML 2154 views | ?
Lei-Yun Wang1,2, Jia-Jia Cui1,2, Tao Zhu1,2, Wei-Hua Shao1,2, Yi Zhao1,2, Sai Wang3, Yu-Peng Zhang3, Ji-Chu Wu4 and Le Zhang3
1Department of Clinical Pharmacology, XiangYa Hospital, Central South University, Changsha 410008, P.R. China
2Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P.R. China
3Department of Neurology, XiangYa Hospital, Central South University, Changsha 410008, P.R. China
4Department of Cardiovascular, Central Hospital of ShaoYang, ShaoYang 422000, P.R. China
Le Zhang, email: [email protected]
Keywords: prostate cancer, biomarker screening, genome-scale, prognosis, gene expression
Received: May 17, 2017 Accepted: August 07, 2017 Published: September 08, 2017
Prostate cancer is a threat to men and usually occurs in aged males. Though prostate specific antigen level and Gleason score are utilized for evaluation of the prostate cancer in clinic, the biomarkers for this malignancy have not been widely recognized. Furthermore, the outcome varies across individuals receiving comparable treatment regimens and the underlying mechanism is still unclear. We supposed that genetic feature may be responsible for, at least in part, this process and conducted a two-cohort study to compare the genetic difference in tumorous and normal tissues of prostate cancer patients. The Gene Expression Omnibus dataset were used and a total of 41 genes were found significantly differently expressed in tumor tissues as compared with normal prostate tissues. Four genes (SPOCK3, SPON1, PTN and TGFB3) were selected for further evaluation after Gene Ontology analysis, Kyoto Encyclopedia of Genes and Genomes pathway analysis and clinical association analysis. MIR1908 was also found decreased expression level in prostate cancer whose target genes were found expressing in both prostate tumor and normal tissues. These results indicated that these potential biomarkers deserve attention in prostate cancer patients and the underlying mechanism should be further investigated.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.